Skip to main content

Table 4 Impact of ASD participants’ characteristics on serum endocannabinoid levels

From: Lower circulating endocannabinoid levels in children with autism spectrum disorder

 

AEA

OEA

PEA

ADOS comparison score [R (P)]#

0.01 (0.9)

0.06 (0.5)

0.07 (0.4)

VABS standard score [R (P)]#

− 0.02 (0.8)

− 0.05 (0.6)

0.09 (0.4)

CARS summary score [R (P)]#

− 0.15 (0.15)

− 0.08 (0.3)

− 0.03 (0.7)

DSM-5: level of support required in social communication [R (P)]#

− 0.11 (0.29)

0.01 (0.89)

0.03 (0.9)

DSM-5: level of support required in repetitive restricted behavior [R (P)]#

− 0.01 (0.9)

0.01 (0.89)

− 0.01 (0.7)

CGI-S, behavior [R (P)]#

− 0.09 (0.3)

0.05 (0.2)

0.13 (0.2)

CGI-S, anxiety [R (P)]#

0.08 (0.8)

0.11 (0.6)

0.07 (0.4)

Family history of ASD [yes/no; χ2 (P)]#

1.13 (0.6)

0.11 (0.73)

1.05 (0.58)

Perinatal complications [yes/no; χ2 (P)]#

0.02 (0.8)

0.53 (0.4)

0.44 (0.8)

Epilepsy comorbidity [yes/no; χ2 (P)]#

0.26 (0.6)

0.64 (0.42)

2.18 (0.3)

ADHD [yes/no; χ2 (P)]#

1.84 (0.07)

1.12 (0.26)

1.5 (0.13)

Medications

 Any [yes/no; χ2 (P)]#

1.71 (0.19)

1.45 (0.2)

3.51 (0.17)

 Antipsychotic [number; R (P)]#

0.18 (0.07)

0.14 (0.17)

0.02 (0.8)

 SSRIs [yes/no; χ2 (P)]#

0.13 (0.7)

0.68 (0.7)

0.48 (0.7)

 Stimulants [yes/no; χ2 (P)]#

0.93 (0.6)

0.94 (0.3)

2.10 (0.3)

 Antiepileptic [yes/no; χ2 (P)]#

0.45 (0.5)

0.58 (0.45)

0.81 (0.37)

HSQ total score [R (P)]#

0.07 (0.5)

− 0.04 (0.7)

0.03 (0.8)

APSI—total score [R (P)]#

− 0.19 (0.06)

− 0.03 (0.7)

0.08 (0.4)

Parents SRS—t score [R (P)]#

− 0.48 (0.6)

0.06 (0.3)

− 0.08 (0.4)

CBCL—externalizing score [R (P)]#

0.04 (0.6)

0.12 (0.2)

0.08 (0.4)

SCQ—summary score [R (P)]#

− 0.02 (0.8)

0.05 (0.6)

0.01 (0.8)

  1. #Results are presented as Pearson correlation coefficient R, (P value) for continuous variables and as Pearson chi-square χ2 (P value) for dichotomous variables (AEA, OEA, PEA cut-off levels)